We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Valneva SE | EU:VLA | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.054 | 1.60% | 3.434 | 3.432 | 3.434 | 3.492 | 3.36 | 3.40 | 312,038 | 16:39:17 |
From May 2022 to May 2024
By Cecilia Butini
Shares in French pharmaceutical company Valneva SE rose in early trading on Monday after the company reported positive data on its vaccine against mosquito-borne viral disease Chikungunya.
At 0827 GMT, shares were up 8.5% at EUR7.32.
The vaccine data focused on persistence of antibodies against Chikungunya after 12 months of receiving a shot, Valneva said. The company also said it didn't identify any safety concerns around the vaccine, confirming the safety profile established in previous trials.
These positive results bode well for an upcoming Biologics License Application with the U.S. Food and Drug Administration, which is expected to be completed by year-end, Bryan Garnier analysts said in a note.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 05, 2022 04:04 ET (09:04 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Valneva Chart |
1 Month Valneva Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
